CLAIMS

1. A composition, which is suitable for topical application to human skin, comprising one or more enzymes , where the composition is:
    a. a pharmaceutical composition, comprising at least one pharmaceutically acceptable ingredient in addition to the one or more enzymes;

    or

    b. a cosmetic composition, comprising at least one cosmetically acceptable ingredient in addition to the one or more enzymes,

    wherein the one or more enzymes are glutamyl endopeptidases having at least 80% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 13.

2. The composition of claim 1, wherein the glutamyl endopeptidases are selected among glutamyl endopeptidases having at least 90% sequence identity; e.g. at least 95% sequence identity; e.g. at least 96% sequence identity; e.g. at least 97% sequence identity; e.g. at least 98% sequence identity; e.g. at least 99% sequence identity; to the polypeptide having the sequence of SEQ ID NO: 1, or SEQ ID NO: 13.

3. The composition of claim 2, wherein the glutamyl endopeptidases are selected among the glutamyl endopeptidase having an amino acid sequence comprising or consisting of SEQ ID NO: 1 or SEQ ID NO: 13, or a variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions in comparison with SEQ ID NO: 1.

4. The composition according to any of the preceding claims , wherein the glutamyl endopeptidases are present in amounts in the range of 1 ng to 10 mg enzyme protein per g of the composition.

5. The composition according to any of the preceding claims, wherein the composition promotes delivery of enzyme to the site of action to facilitate its function and purpose formulated as a gel, cream such as semisolid emulsions of a hydrophilic and a hydrophobic phase, semisolid and/or liquid including nano- and microemulsions and more than two phases, cloth, sponge, paste, pellet, shampoo, soap, jelly, lotion, foam, ointment, film, spray, solution, liquid, oil, ointment, suspension of subnano- to micrometer sized particles in a liquid or solid suspension, medical patch, medical patch with microneedles, medical patch with dissolving microneedles, derma roller with microneedles, iontophoresis, compressed air pressure, solid skin implant, semi-solid skin implant, liquid skin implant, skin tattoo, roll-on, swab, syrup, tape, wafer or injectable liquid, injectable solution, injectable emulsion, or injectable suspension.

6. A medical device comprising a pharmaceutical composition according to any of the preceding claims.

7. The medical device of claim 6, wherein the medical device is a patch or hollow needle comprising the composition.

8. Use of the composition according to any one of claims 1-5 in the manufacture of a medicament for treating follicular dermatoses or hair follicle-linked conditions, wherein the composition is a pharmaceutical composition.

9. The use according to claim 8, wherein the hair follicle-linked condition or follicular dermatoses is selected among: Hirsutism, Hypertrichosis or Pseudofolliculitis barbae; or follicular dermatoses that are induced by follicular hyperkeratosis or follicular occlusion that leads to development of Acne vulgaris, Keratosis pilaris, Dowling-Degos disease, Hailey-Hailey disease, Mammilary fistula or follicular occlusion tetrad syndromes including Acne conglobata, Pilonidal sinus disease, Dissecting cellulitis of the scalp and Hidradenitis suppurativa; or inflammatory hair follicle-linked conditions including Follicular psoriasis, Pityriasis Rubra Pilaris, Discoid Lupus, Lichen Planopilaris, Hypertophic Lichen Planopilaris, Lichen Planus Follicularis Tumidus, Lichen Schlerosus, Lichen Spinulosus, Wong-type dermatomyositis, infectious hair follicle-linked conditions including Post-Kala Azar dermal Leishmaniasis, Type I Reactions in borderline tuberloid leprosy, Pityriasis Folliculorum; and other hair follicle-linked disesases including Nevus Comedonicus, Folliculotropic Mycosis Fungoides and Phyrnoderma.

10. The use according to claim 8 or 9, wherein the medicament is used to prevent the development of follicular dermatoses and hair follicle-linked conditions in a susceptible individual.

11. A non-therapeutic use of the composition according to any one of claims 1-5 for removal of undesired hair, wherein the composition is a cosmetic composition.

12. A non-therapeutic use of the composition according to any one of claims 1-5 for skin peeling, wherein the composition is a cosmetic composition.

13. The use according to any one of claims 8-12, wherein the composition promotes delivery to the skin and hair follicle of the one or more proteins such as enzymes including themselves.

14. The use according to claim 8 or 9, wherein the composition enhances follicular and skin delivery of other pharmaceuticals ingredients.

15. The use according to claim 11 or 12, wherein the composition enhances follicular and skin delivery of other cosmetic ingredients.

16. The use according to claim 14 or 15, wherein the composition enhances the permeability of other small and large compounds to hair follicles.

17. The composition according to any one of claims 1-5 for use as a medicament.

18. The composition according to any one of claims 1-5 for use as a pharmaceutical in the treatment of human hair follicle-linked conditions and follicular dermatoses.

19. The composition according to any one of claims 1-5 for use in the treatment of Hirsutism, Hypertrichosis or Pseudofolliculitis barbae; or follicular dermatoses that are induced by follicular hyperkeratosis or follicular occlusion that leads to development of Acne vulgaris, Keratosis pilaris, Dowling-Degos disease, Hailey-Hailey disease, Mammilary fistula or follicular occlusion tetrad syndromes including Acne conglobata, Pilonidal sinus disease, Dissecting cellulitis of the scalp and Hidradenitis suppurativa; or inflammatory hair follicle-linked conditions including Follicular psoriasis, Pityriasis Rubra Pilaris, Discoid Lupus, Lichen Planopilaris, Hypertophic Lichen Planopilaris, Lichen Planus Follicularis Tumidus, Lichen Schlerosus, Lichen Spinulosus, Wong-type dermatomyositis, infectious hair follicle-linked conditions including Post-Kala Azar dermal Leishmaniasis, Type I Reactions in borderline tuberloid leprosy, Pityriasis Folliculorum; and other hair follicle-linked disesases including Nevus Comedonicus, Folliculotropic Mycosis Fungoides and Phyrnoderma.